Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. - Test2 - elhamkhani - TriplyDB

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

http://www.wikidata.org/entity/Q34161651

about

ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383 Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue.Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.Species differences in drug transporters and implications for translating preclinical findings to humans.Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.Primary hepatocyte cultures as prominent in vitro tools to study hepatic drug transporters.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.In vitro methods to support transporter evaluation in drug discovery and development.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Dealing with the complex drug-drug interactions: towards mechanistic models.Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.Modeling Physiological Events in 2D vs. 3D Cell Culture.Prediction of Hepatic Efflux Transporter-Mediated Drug Interactions: When Is it Optimal to Measure Intracellular Unbound Fraction of Inhibitors?The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer.Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.Mechanistic investigations into the species differences in pinometostat clearance: impact of binding to alpha-1-acid glycoprotein and permeability-limited hepatic uptake.Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels.

P2860

Q27022933-CA582D39-4533-4B33-92C8-501234123F6C Q28088352-79FD7CDA-1B6C-4FF6-B088-3570A53CEB28 Q30776360-69639B63-3F77-45D1-90D7-12A32C714769 Q31054926-B6DEDDED-B928-40A5-ACCF-7E0FD4AB601F Q31116232-52BF605D-BFAC-4B36-9B98-3C8A360A1910 Q33994570-804784FC-4E5A-4D13-A647-6567572DDDA1 Q34330504-0FB4575D-14F7-460F-9E4E-70FCDFE7E907 Q35560052-8BD94449-A13B-42D6-92A2-826EAB93E890 Q36234390-179BD5C3-B257-43F2-88A9-13B95FC4C8B2 Q36599597-2BC35D79-74A9-41ED-830D-5B839634FA7E Q36693701-E6FED397-12CB-43FC-A116-BAA9BB97F428 Q36910606-852613C7-D70C-444C-9C84-B4B60AE9EC27 Q36972804-7C6560A3-2518-4C56-B4E9-28ED5F924A15 Q37251993-0176EA38-F1F2-4254-A8F9-994614054422 Q37279044-BD58E0AB-6ADA-4A97-B021-366E99EB016A Q37331801-1BFFE980-C80C-4C74-85AC-64203459141D Q37470663-25ECA08A-F121-491A-ABB0-8EA280C6666F Q37504548-D7AD3BF7-DA4A-4E92-AED0-D68F4D4E88D7 Q38050686-31036CC8-23C8-4924-99AD-2F1FA8FBAB84 Q38068912-4746A8BA-21E5-4EE9-8083-7524AA08B5D7 Q38075057-4BC40A7F-ACDF-4690-A8F6-6627C2103517 Q38077993-56E9C33F-C5BE-4C73-A4A9-EBF75DF2962C Q38087695-1FA11DB3-8CDC-4E46-B30D-738B871C8583 Q38099194-55895E87-AD42-409E-BFC6-1D915AD668D4 Q38109095-2A3F1F9D-3FAD-4E35-8267-BDBCB59474B4 Q38214334-4A5F035C-23E0-4391-B877-AE6E3B399BB6 Q38233298-2351903C-296D-4BDA-BC67-B5E952520D99 Q38302225-8890F139-D4F9-4EBB-A8C6-72A6D563FF64 Q38351385-C0325275-0AF1-432D-A485-C85D285DC4B6 Q38671020-BD17BD41-FBED-43C8-A188-CDCE80059138 Q38688370-012A7FBF-C3FB-4975-8D60-810EB1671FAD Q38844656-82C4A617-619F-4BCA-81AE-D80C6334A2F7 Q38855314-19F08413-1607-418C-8C8D-A5FAB74A66DF Q38992427-D9F9FA77-6B5D-47C6-BBB5-5313A80A6353 Q39101424-DBC949D9-C870-44B4-B4D2-CCD9D84508C7 Q39178447-8E8300BD-BCCE-4D38-B22F-31BDF6177901 Q39212609-715090CE-212D-4C1D-91A1-866E908599D1 Q39773424-0272E174-D1FF-4E7B-A69B-1CD0F6FA8F56 Q39782124-479EFEE9-8AED-47D3-A3A5-5C78BEB38DED Q39984138-AF54F80A-6CC3-4453-9F6C-2363886010E2

P2860

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

http://www.wikidata.org/entity/Q34161651

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Mechanistic pharmacokinetic mo ...... culture human hepatocyte data.

@ast

Mechanistic pharmacokinetic mo ...... culture human hepatocyte data.

@en

Mechanistic pharmacokinetic mo ...... culture human hepatocyte data.

@nl

type

label

Mechanistic pharmacokinetic mo ...... culture human hepatocyte data.

@ast

Mechanistic pharmacokinetic mo ...... culture human hepatocyte data.

@en

Mechanistic pharmacokinetic mo ...... culture human hepatocyte data.

@nl

prefLabel

Mechanistic pharmacokinetic mo ...... culture human hepatocyte data.

@ast

Mechanistic pharmacokinetic mo ...... culture human hepatocyte data.

@en

Mechanistic pharmacokinetic mo ...... culture human hepatocyte data.

@nl

P1433

Q34161651-A4139F6B-6143-4193-B1B1-D41232BEE569

P1476

Q34161651-D6EC6F1B-5329-45BB-84E8-22C8EFAAEFF9

P2093

Q34161651-13641F27-EE25-4ACC-AB30-B1CA27937463

Q34161651-1B96E0A5-A030-4ACF-8BDB-AB89EDD74769

Q34161651-287DE317-1762-4AD5-B1FF-8C64BAE42626

Q34161651-62F0B23A-0C47-40CA-9BAC-B50A3B8E6F0A

Q34161651-84A09A44-8A11-4F81-84FA-403746518AF5

Q34161651-9D5134E0-3464-4864-A6BE-A2C6778DCD7D

Q34161651-A16DB6F8-924D-465A-995D-A54CF38F8CE8

Q34161651-A38ADE49-FCDD-4A0B-A7A3-9693A01F26A4

Q34161651-DB04C94B-C359-467A-B458-74F99F3F0380

P304

Q34161651-940D97E4-E782-4007-B316-643557CAC070

P31

Q34161651-8B55877A-58B0-4E2B-A326-1005F86BC75A

P356

Q34161651-35134CB4-7EC8-41BE-AB93-0BEFB66BC035

P433

Q34161651-733A7B0F-EA30-4CC9-B07D-6F6EC25D941E

P478

Q34161651-A8CBCC34-7DCD-4400-915A-968939B18C09

P50

Q34161651-4AB24A32-0C7B-47AC-860B-2233344C6EC0

Q34161651-71E34DE7-85CA-49E7-B147-A0AB5198EEAA

P577

Q34161651-D6C35973-2746-43BE-A54C-D979E8BE7B3B

P5875

Q34161651-058CE0DF-C33B-4C60-A4CB-406BFA4799FF

P698

Q34161651-D26669DD-DCD7-49E0-8B51-D7E3BB0F9BF3

P356

P1433

Drug Metabolism and Disposition

P1476

Mechanistic pharmacokinetic mo ...... culture human hepatocyte data.

@en

P2093

Ayman El-Kattan

http://www.w3.org/2001/XMLSchema#string

Emi Kimoto

http://www.w3.org/2001/XMLSchema#string

Hannah M Jones

http://www.w3.org/2001/XMLSchema#string

Hugh A Barton

http://www.w3.org/2001/XMLSchema#string

J Brian Houston

http://www.w3.org/2001/XMLSchema#string

Katherine S Fenner

http://www.w3.org/2001/XMLSchema#string

Sarah Kempshall

http://www.w3.org/2001/XMLSchema#string

Sonya C Tate

http://www.w3.org/2001/XMLSchema#string

Yi-An Bi

http://www.w3.org/2001/XMLSchema#string

P304

1007-1017

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.111.042994

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Aleksandra Galetin

P577

2012-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221842184

http://www.w3.org/2001/XMLSchema#string

P698

22344703

http://www.w3.org/2001/XMLSchema#string